Abstract 168P
Background
In the past decade, radiotherapy (RT) has been widely practised for treating extensive-stage small cell lung cancer (ES-SCLC). Despite this, it has been discouraged in phase III trials of first line chemoimmunotherapy. Instead, robust rationales have emerged in favour of using RT as a booster to promote a sustained anti-tumour immune response. On basis of published data defining a subtype of SCLC patients who respond to chemotherapy (CT) classified as \"inflamed\" and expressing high innate immune genes such as the STimulator of INterferon pathway (STING) pathway and based on further preclinical data supporting STING levels as potential biomarkers of response to combined chemo- and immunotherapy, we hypothesised that innate immune activation may provide an opportunity to evaluate anti-tumour immune activity in vitro.
Methods
We explored the landscape of STING, Mitochondrial antiviral-signaling protein (MAVS), Gamma-interferon-inducible protein (IFI-16) and immune-related cytokines expression both at mRNA and protein expression levels among two SCLC cell lines, namely H82 and H524. We then tested the effect of in vivo treatment with CT and RT (4 Gy dose) on PBMC subpopulations derived from SCLC patients by LDH cytotoxicity assay.
Results
We performed sequential in vitro treatment with CT and RT (4 Gy) in selected SCLC cell lines and we investigated changes in STING pathway, as indicator of DNA damage induced by CT and RT. cGAS, STING and downstream protein p-TBK1 and p-IRF3 were upregulated by CT plus RT in both cell lines. Interestingly, these increments were accompanied by high levels of DNA damage, as suggested by increased levels of H2A.X, ATM, ATR, and DNA-PK. IFI-16 DNA sensor was also increased at both protein and mRNA levels. Moreover, inflammatory T cells recruiting the chemokines IL6, IFN-β, CXCL5, CXCL10, were also significantly increased by sequential treatment with CT and RT. The SCLC patients-derived immune cells activity patients were also significantly increased post-RT as measured by LDH cytotoxicity assay.
Conclusions
We demonstrated in cellular models of SCLC a positive modulation of innate immune pathways with CT and RT sequential treatment, suggesting a possible boost role of RT in SCLC patients treated with chemoimmunotherapy.
Legal entity responsible for the study
The authors.
Funding
AIRC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - A Novel Allosteric Oral Immunotherapy Small Molecule Modulates Adenosine 2A Receptor Signaling and Restores Anti-Tumor Immune Responses
Presenter: David Pejoski
Session: Poster Display
147P - Pre-clinical evaluation and safety profile of the highly selective anti-VISTA antibody K01401-020
Presenter: Geneviève Gueguen Dorbes
Session: Poster Display
148P - HexaBody-OX40, a novel Fc_ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo
Presenter: Kristel Kemper
Session: Poster Display
149P - HLA/SIRPa bispecifics-A novel multitarget therapeutic strategy to induce potent anti-tumor immune responses
Presenter: anahita rafiei
Session: Poster Display
150P - Chemotherapy in combination with Toll-like receptor agonism promoted antitumor immune response in triple negative breast cancer
Presenter: Eunice Dotse
Session: Poster Display
151P - Tumor organoid-derived TIL therapy for colorectal cancer
Presenter: Marc Leushacke
Session: Poster Display
152P - Discovery of best-in-class dual-acting A2AR/A2BR antagonists that are functional in high adenosine environment
Presenter: Nainesh Katagihallimath
Session: Poster Display
153P - Discovery of a Novel, Dual CD73 and PD-1 Targeting Multispecific Drug Fc-Conjugate (DFC) for the Treatment of Cancer
Presenter: James Levin
Session: Poster Display
154P - Computer-aided drug design based on CLDN4 ligand and its biological evaluation in ovarian cancer
Presenter: Yi Xu
Session: Poster Display
155P - A Phase 1 Study Exploring the Safety and Tolerability of the Small-Molecule PD-L1 Inhibitor INCB099280 in Select Advanced Solid Tumors
Presenter: Hans Prenen
Session: Poster Display